Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Total Current Liabilities (2021 - 2025)

Kezar Life Sciences' Total Current Liabilities history spans 5 years, with the latest figure at $13.4 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 34.52% year-over-year to $13.4 million; the TTM value through Sep 2025 reached $13.4 million, down 34.52%, while the annual FY2023 figure was $17.7 million, 61.35% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $13.4 million at Kezar Life Sciences, down from $17.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $20.4 million in Q3 2024 and bottomed at $5.9 million in Q2 2021.
  • The 5-year median for Total Current Liabilities is $13.4 million (2025), against an average of $12.4 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 95.53% in 2023 before it crashed 34.52% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $8.2 million in 2021, then surged by 33.91% to $11.0 million in 2022, then soared by 61.35% to $17.7 million in 2023, then grew by 15.13% to $20.4 million in 2024, then crashed by 34.52% to $13.4 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Total Current Liabilities are $13.4 million (Q3 2025), $17.0 million (Q1 2025), and $20.4 million (Q3 2024).